SciSparc Bags Another Patent, Strengthening its Core Technology in Canada
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced it has been granted a Canadian patent for its core technology combining cannabinoids and n-acylethanolamines. This patent is expected to strengthen SciSparc's proprietary technology, enhancing the safety of cannabinoids by using low dosages while maintaining therapeutic benefits.
March 18, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc Ltd. has been granted a Canadian patent for its core technology, potentially enhancing the company's product safety and efficacy.
The granting of a patent in Canada for SciSparc's core technology is a significant development for the company. It not only strengthens its intellectual property portfolio but also potentially increases the safety and efficacy of its cannabinoid-based therapies. This could lead to increased investor confidence and potentially positive market reactions in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90